Navigation Links
Proteolix Raises $79 Million in Series C Financing
Date:9/8/2008

Funds to Support Clinical Development of Carfilzomib

Paul Hastings Appointed to Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 8 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced the successful completion of a new financing round of $79 million. The Series C round was led by new investor Nomura Phase4 Ventures. New investor Westfield Capital Management and existing investors, Advanced Technology Ventures, Delphi Ventures, Latterell Venture Partners, U.S. Venture Partners and The Vertical Group, all participated in the financing.

Proceeds from the financing will primarily support the completion of the company's ongoing Phase 2 clinical trials of carfilzomib, and the advancement of this anti-cancer therapeutic into Phase 3 clinical trials for the treatment of multiple myeloma. Proteolix will also use the funds to advance candidates in the company's earlier stage pipeline of proteasome inhibitors.

"We are pleased to have completed this significant financing with participation from such highly-regarded new and existing investors," said Susan Molineaux, Ph.D., Proteolix's Chief Executive Officer. "Our lead candidate, carfilzomib, has demonstrated promising results in clinical and preclinical studies in multiple myeloma and a variety of other tumor types. Proceeds from this financing will enable us to advance carfilzomib to registration studies for multiple myeloma while continuing to cultivate select early-stage assets in our pipeline."

"We have been impressed by Proteolix's team, pipeline and proprietary expertise in the area of proteasome drug discovery and development. In particular, carfilzomib has been designed to be a highly selective candidate against a validated target and has demonstrated promising clinical data in hematologic malignancies," said Denise Pollard-Knight, Ph.D., Managing Director of Nomura Phase4 Ventures.

Carfilzomib is currently in Phase 2 clinical studies to evaluate its safety and efficacy in hematologic and solid tumor malignancies. In non- clinical studies, carfilzomib has consistently exhibited a high level of selectivity for a single active site in the proteasome, and the reported clinical data to-date indicate the drug is well tolerated. The company's most advanced clinical trials of carfilzomib are evaluating the compound's activity among multiple myeloma patients who have failed or relapsed following prior therapy. In addition to carfilzomib, Proteolix has generated a rich pipeline, including an oral anti-cancer proteasome inhibitor as well as a selective inhibitor targeting the proteasome in the cells of the immune system.

New Board Member Announced

Proteolix is also pleased to announce that Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals, Inc., has joined its Board of Directors. Mr. Hastings brings more than 20 years of biotechnology and pharmaceutical industry experience as a senior-level executive in public and private companies. "Proteolix has made great progress in advancing its lead cancer therapeutic through clinical trials and developing an earlier stage pipeline of proteasome inhibitors," said Mr. Hastings on behalf of Proteolix's Board of Directors. "I personally look forward to working closely with the team on their continued success."

Mr. Hastings also serves on the board of directors of Cerimon Pharmaceuticals, Inc. and serves as a director of the Biotechnology Industry Organization (BIO) and BayBIO.

About Proteolix

Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib (PR-171), is currently in multiple Phase 2 clinical studies to evaluate its safety and efficacy in hematologic and solid tumor malignancies. Proteolix is also developing a pipeline of novel proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor. For additional information on Proteolix, please visit http://www.proteolix.com.

Contact information

Investors: Media Inquiries:

Matthew Ferguson BCC Partners

Chief Financial Officer Karen L. Bergman or Michelle Corral

650-266-2825 650-575-1509 or 415-794-8662

investors@proteolix.com


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Pearl Therapeutics Raises $15.5 Million in Private Financing
4. Enobia Pharma Raises $40.1 Million Series B Financing
5. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
6. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
7. VisEn Medical Raises $7 Million in Series B Financing
8. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
9. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
10. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
11. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... 25, 2017 , ... Avery Products Corporation, the world’s largest ... printing, is proud to announce that it has won two more awards for ... at avery.com/GHS . The products were recently honored with the ASSE Safety ...
(Date:7/26/2017)... ... 25, 2017 , ... In this webinar , which ... considerations needed for designing ideal guide RNAs and DNA oligo or plasmid repair ... double-strand breaks in genomic DNA has greatly simplified strategies for precise gene editing ...
(Date:7/26/2017)... Jacksonville, FL (PRWEB) , ... July 26, 2017 ... ... deep learning algorithms targeted towards leveraging the years of diagnostic excellence by Mayo ... Logix. The first product suite will be distributed through the Microsoft Azure ...
(Date:7/26/2017)... July 26, 2017  Nurse practitioners play a crucial role ... of a Merck Manuals survey released today. The ... revealed that most (88 percent) believe they spend at least ... prescriptions. ... Merck Manuals survey of 210 nurse practitioners finds ...
Breaking Biology Technology:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):